COSCIENS Biopharma Inc.
CSCI.TO
TSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 32.34% | -1,200.70% | -4,160.78% | -1,811.79% | -814.71% |
| Total Depreciation and Amortization | -26.07% | -49.01% | -29.21% | -24.38% | -22.74% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -75.73% | 248.59% | 266.77% | 351.62% | 459.70% |
| Change in Net Operating Assets | 111.61% | 134.59% | -296.35% | -167.46% | -775.81% |
| Cash from Operations | 41.75% | -318.14% | -953.97% | -644.67% | -452.23% |
| Capital Expenditure | 38.85% | 37.63% | 23.23% | 9.21% | -44.76% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -100.00% | -100.00% | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -98.07% | -105.31% | 2,637.50% | 2,637.50% | 2,687.50% |
| Cash from Investing | -101.83% | -103.95% | -103.64% | 1,963.89% | 3,196.67% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 17.61% | 22.34% | 4.31% | -20.93% | -4.48% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 74.85% | -82.43% | -- | -- | -- |
| Cash from Financing | 33.28% | 8.90% | -40.24% | -62.36% | -48.78% |
| Foreign Exchange rate Adjustments | 219.43% | 321.74% | 491.38% | -108.99% | -160.11% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -193.53% | -152.97% | -170.94% | 941.87% | 197.91% |